摘要
目的探讨三种不同药物降尿酸治疗慢性肾脏病合并高尿酸血症的临床疗效。方法回顾性分析2014年8月—2017年8月我院收治的102例慢性肾脏病合并高尿酸血症患者的临床资料,应用随机数字表法将其分为三组,每组34例,其中加用非布司他治疗患者为非布司他组,加用别嘌醇治疗患者为别嘌醇组,加用苯溴马隆治疗患者为苯溴马隆组,比较三组患者的临床疗效、不良反应、血肌酐及尿酸水平。结果 (1)非布司他组临床治疗总有效率高于苯溴马隆组和别嘌醇组(97.06%vs.73.53%vs.70.59%)(P<0.05);(2)三组治疗后血尿酸、肌酐水平均较治疗前降低(P<0.05);非布司他组治疗后血尿酸、肌酐水平均低于别嘌醇组和苯溴马隆组(P<0.05)。结论非布司他治疗慢性肾脏病合并高尿酸血症患者的临床疗效更为显著,可明显降低血尿酸、肌酐水平,且副作用较小。
Objective To investigate the clinical efficacy of three different drugs on uric acid lowering in chronic kidney disease with hyperuricemia.Methods The clinical and follow-up data of 102 patients with chronic kidney disease complicated with hyperuricemia admitted in author＇s hospital from August 2014 to August2017 were retrospectively analyzed.All patients were divided into three groups and received conventional symptomatic treatment.Patients receiving Febuxostat,Allopurinol and Benzbromarone were included into febuxostat group,allopurinol group and benzbromarone group respectively,and thirty-four cases in each group.The clinical efficacy,serum creatinine and uric acid levels were compared among the three groups,and the incidence of adverse reactions in the three groups was also recorded.Results The total effective rate of clinical treatment in febuxostat group was significantly higher than that in benzbromarone group and allopurinol group（97.06% vs 73.53%,70.59%,P〈0.05）;Serum uric acid and creatinine levels were significantly decreased in all three groups（P〈0.05）,and those levels were the lowest in the febuxostat group than in the benzbromarone group and allopurinol group（P〈0.05）.Conclusion The clinical efficacy of Febuxostat relative to Allopurinol and Benzbromarone in the treatment of patients with chronic kidney disease and hyperuricemia is more significant,which can significantly reduce the serum uric acid,creatinine levels with less side effects.
作者
勾威
郭丽环
王钒
栾夏青
王健美
申丽盈
庄金刚
Go Wei;Guo Lihuan;Zhuang Jinggang(Department of Rheumatology Immunology, China National Petroleum Corporation Central Hospital ,Langf ang 065000 ,Chin)
出处
《中国煤炭工业医学杂志》
2018年第2期148-151,共4页
Chinese Journal of Coal Industry Medicine
基金
廊坊市科技计划项目(编号:2014013119)
